Early postoperative chemotherapy reduces risk of death in patients with colorectal cancer
Early chemotherapy after surgery improves survival for colorectal cancer patients
This meta-analysis of cohort studies involving 72,873 patients found that delayed postoperative chemotherapy significantly increased the ris…
Starting chemotherapy within 8 weeks of surgery significantly improves survival rates for people living with colorectal cancer.
Chemoimmunotherapy improves objective response rate and survival in advanced pulmonary large-cell neuroendocrine carcinoma
Combining Chemotherapy and Immune Therapy Improves Outcomes for Advanced Lung Cancer
This meta-analysis of 3537 patients with advanced pulmonary large-cell neuroendocrine carcinoma (LCNEC) found that chemoimmunotherapy signif…
Adding an immune-boosting drug to standard chemotherapy helps patients with a specific type of advanced lung cancer live longer.
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
Immunotherapy plus chemo improves survival in triple-negative breast cancer
This umbrella meta-analysis of 39,147 patients found that combining immune checkpoint inhibitors with chemotherapy significantly improves ov…
Adding immunotherapy to chemo helps some patients with advanced triple-negative breast cancer live longer, but side effects are more common.
Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
New Guidelines Redefine Surgery Options for Lung Cancer Patients
This clinical guideline addresses the management of stage III non-small cell lung cancer (NSCLC). It advocates for a multidisciplinary appro…
New guidelines suggest that surgery for certain lung cancers should be based on tumor biology and treatment response rather than just anatom…
Surgical treatment and multimodal therapies characterize management options for rare penile melanoma cases
Treatment Options and Clinical Features for Penile Melanoma
This case series and narrative review describes the clinical features and treatment landscape for patients with penile melanoma. The authors…
New research highlights surgical options and targeted therapies for penile melanoma, a rare form of skin cancer that primarily affects middl…
PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
Adding PD-1 inhibitors to chemotherapy improves lung cancer survival
This network meta-analysis of 20 randomized controlled trials evaluated treatments for driver gene-negative non-small cell lung cancer with …
Combining a specific immunotherapy drug with chemotherapy may help patients with certain types of lung cancer and liver spread live longer.
Immune checkpoint inhibitor regimens for colorectal cancer increase risk of endocrine adverse events
Immunotherapy for colon cancer linked to thyroid problems
This network meta-analysis evaluates endocrine toxicity in patients with colorectal cancer treated with immune checkpoint inhibitor (ICI) ba…
New analysis finds immunotherapy for colorectal cancer raises risk of thyroid issues, especially with certain drug combos.
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Pediatric Langerhans Cell Histiocytosis presents with skull involvement in 48.8% of cases
New data clarifies treatment outcomes for children with LCH
This systematic review and meta-analysis of 885 patients identifies common otolaryngologic manifestations in pediatric Langerhans Cell Histi…
Children with Langerhans Cell Histiocytosis and head or neck symptoms may have high remission rates but face risks of recurrence.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
Adding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer
This systematic review and meta-analysis of phase II and III trials evaluated angiogenesis inhibitors combined with chemotherapy versus chem…
A large review of eight thousand four hundred patients found that adding angiogenesis inhibitors to standard chemotherapy improved how long …
Systemic cancer treatment linked to 5% skeletal muscle loss over 90 days
Cancer treatment linked to muscle loss in large analysis
A systematic review and meta-analysis of 78 studies (n=10,502) found that systemic cancer treatment is associated with a small but significa…
Chemotherapy and immunotherapy may cause muscle loss in cancer patients, a new analysis of 78 studies finds.